Claudin 18.2抗体偶联药物的临床研究进展  

Clinical research progress on Claudin 18.2 antibody-drug conjugates

作　　者：练晓彤 雷宇[2] LIAN Xiao-tong;LEI Yu(Guangxi Medical University,Nanning 530021,China;Guangxi Medical University Affiliated Tumor Hospital,Nanning 530021,China)

机构地区：[1]广西医科大学,南宁530021 [2]广西医科大学附属肿瘤医院,南宁530021

出　　处：《中国新药杂志》2025年第7期720-726,共7页Chinese Journal of New Drugs

摘　　要：紧密连接蛋白亚型Claudin18.2(CLDN18.2)仅在正常胃黏膜上皮细胞中表达,调控物质跨膜运输。但在正常组织的恶性转化中CLDN18.2得以保留,在胃癌、胰腺癌、乳腺癌等多种恶性肿瘤中普遍表达。以CLDN18.2为靶点的抗体偶联药物(antibody-drug conjugates,ADC)同时具有单克隆抗体的高靶向选择性和细胞毒性药物的高抗肿瘤活性,是极具治疗前景的新型生物靶向抗肿瘤药物。本文对CLDN18.2 ADC的临床试验进展进行综述,为相关药物的研发提供一定参考。The tight junction protein subtype Claudin18.2(CLDN18.2) is exclusively expressed in normal gastric mucosal epithelial cells,where it plays a crucial role in regulating transmembrane transport of substances.However,CLDN18.2 is retained in the malignant transformation of normal tissues,and is widely expressed in gastric cancer,pancreatic cancer,breast cancer and other malignant tumors.Antibody-drug conjugates(ADC) targeting CLDN18.2 simultaneous exhibit high targeting selectivity of monoclonal antibodies and high anti-tumor activity of cytotoxic drugs,making them a promising new type of biologically targeted anticancer drug with great therapeutic potential.This article reviews the clinical trial progress of CLDN18.2 ADC,providing some references for the development of related drugs.

关 键 词：Claudin 18.2 抗体偶联药物 靶向治疗 

分 类 号：R979.1[医药卫生—药品]